Antiandrogen-Equipped Histone Deacetylase Inhibitors Selectively Inhibit Androgen Receptor (AR) and AR-Splice Variant (AR-SV) in Castration-Resistant Prostate Cancer (CRPC).
Balaji ChandrasekaranSubhasish TapadarBocheng WuUttara SaranAshish TyagiAlexis JohnstonDavid A GaulAdegboyega K OyelereChendil DamodaranPublished in: Cancers (2023)
These results demonstrate that SBI-46 is a potent agent that inhibits preclinical models of CRPC by downregulating the expressions of both AR and AR-SV. Furthermore, these results suggest that SBI-46 may be a potent compound for treating CRPC.